KELLY JARED (Chief Executive Officer) purchased 47.5% of their position (35.10K shares) of ONCOLYTICS BIOTECH INC on the open market
Open‑market purchase worth $29.5K — a major conviction buy. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 2/13/2026ACC: 0001493152-26-006545
DirectorOfficer· Chief Executive Officer
Since Feb 2026
+35.10K
Net shares
Net buyer
$29.5K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
35.10K acquired
Non-Derivative Transactions2
Common Shares
Direct
Shares
+5.60K
Price / share
$0.84
Trade value
$4.68K
% of position
7.6%
2/11/2026
73.90K→79.50K
Common Shares
Direct
Shares
+29.50K
Price / share
$0.84
Trade value
$24.84K
% of position
37.1%
2/12/2026
79.50K→109K
Total
Net shares
+35.10K
Net value
$29.52K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 2/11/2026 | P · Purchase | +5.60K | $0.84 | $4.68K | 7.6% | 73.90K | 79.50K |
| Common Shares Direct | 2/12/2026 | P · Purchase | +29.50K | $0.84 | $24.84K | 37.1% | 79.50K | 109K |
| Total | +35.10K | $29.52K | ||||||
Derivative Transactions0
No derivative transactions reported